Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
Authors
Keywords
Sorafenib, Hepatocellular carcinoma, Fluorescence in situ hybridization, pERK, Prognosis, Mcl-1
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 139, Issue 7, Pages 1179-1187
Publisher
Springer Nature
Online
2013-04-08
DOI
10.1007/s00432-013-1429-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Delving deeper: MCL-1's contributions to normal and cancer biology
- (2012) Rhonda M. Perciavalle et al. TRENDS IN CELL BIOLOGY
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
- (2009) Y. Hoshida et al. CANCER RESEARCH
- Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
- (2009) L. Jilaveanu et al. CLINICAL CANCER RESEARCH
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
- (2008) Q. Ding et al. CANCER RESEARCH
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q
- (2008) Tae-Min Kim et al. INTERNATIONAL JOURNAL OF CANCER
- EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
- (2008) Shi-Xu Jiang et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- (2007) Klaus Juergen Schmitz et al. JOURNAL OF HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now